[{"id":6262,"regimens":[{"id":12024,"duration":{"id":6022,"approximate_duration":"5days","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9275,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12024},{"id":9276,"answer":"In a novel combination with another drug","answer_other":"","regimen":12024}],"created":"2020-10-13T22:12:23.386972Z","updated":"2020-10-13T22:20:59.902545Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6262},{"id":12025,"duration":{"id":6023,"approximate_duration":"5days","dates_unknown":true},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":9277,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12025},{"id":9278,"answer":"In a novel combination with another drug","answer_other":"","regimen":12025}],"created":"2020-10-13T22:12:23.394755Z","updated":"2020-10-13T22:20:59.908935Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6262},{"id":12026,"duration":{"id":6024,"approximate_duration":"dose 1 over 2hours/ dose 2 over 22hours","dates_unknown":true},"drug":{"id":5812,"name":"Alteplase","url":"cure-api2.ncats.io/v1/drugs/5812","rxNorm_id":null,"notes":null},"use_drug":[{"id":9279,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12026},{"id":9280,"answer":"In a novel combination with another drug","answer_other":"","regimen":12026}],"created":"2020-10-13T22:12:23.401015Z","updated":"2020-10-13T22:20:59.914473Z","dose":"25mg","frequency":"2 doses","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6262}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14015,"answer":"Clinical assessment","answer_other":"","report":6262},{"id":14016,"answer":"Imaging","answer_other":"","report":6262},{"id":14017,"answer":"PCR","answer_other":"","report":6262}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4309,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6262}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-13T22:03:57.701195Z","updated":"2020-10-13T22:20:59.894587Z","title":"Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32267998,"doi":"10.1111/jth.14828","article_url":"https://pubmed.ncbi.nlm.nih.gov/32267998/","pub_year":2020,"published_authors":"Wang J\r\nHajizadeh N\r\nMoore EE\r\nMcIntyre RC\r\nMoore PK\r\nVeress LA\r\nYaffe MB\r\nMoore HB\r\nBarrett CD","article_author_email":"Author email could not be found.","journal":"Journal of thrombosis and haemostasis : JTH","abstract":"A prothrombotic coagulopathy is commonly found in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID-19 respiratory failure is a relatively preserved lung compliance and high Alveolar-arterial oxygen gradient, with pathology reports consistently demonstrating diffuse pulmonary microthrombi on autopsy, all consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of low-compliance in ARDS. The COVID-19 pandemic is overwhelming the world's medical care capacity with unprecedented needs for mechanical ventilators and high rates of mortality once patients progress to needing mechanical ventilation, and in many environments including in parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality and marked improvements in oxygenation. Here we report a series of three patients with severe COVID-19 respiratory failure who were treated with tissue plasminogen activator. All three patients had a temporally related improvement in their respiratory status, with one of them being a durable response.","article_type":"Original","study_type":"Case Series","number_of_patients":3,"article_patient_number":"1","full_text_available":true,"outcome":"Patient died","surgery":"No","age":"71-80 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":true,"hypertension":true,"cardiovascular_disease":true,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lung","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"After a period of follow-up","follow_up_period":"11days","relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"the patient descended into multiple organ failure with refractory hypotension secondary to arrhythmia and superimposed bacterial infection and died.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5812,6122,8342]},{"id":6263,"regimens":[{"id":12027,"duration":{"id":6025,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":9281,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12027},{"id":9282,"answer":"In a novel combination with another drug","answer_other":"","regimen":12027}],"created":"2020-10-13T22:55:01.521712Z","updated":"2020-10-13T23:01:15.683337Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6263},{"id":12028,"duration":{"id":6026,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9283,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12028},{"id":9284,"answer":"In a novel combination with another drug","answer_other":"","regimen":12028}],"created":"2020-10-13T22:55:01.529836Z","updated":"2020-10-13T23:01:15.689815Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6263},{"id":12029,"duration":{"id":6027,"approximate_duration":"2hours dose1/ 22hours dose 2","dates_unknown":true},"drug":{"id":5812,"name":"Alteplase","url":"cure-api2.ncats.io/v1/drugs/5812","rxNorm_id":null,"notes":null},"use_drug":[{"id":9285,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12029},{"id":9286,"answer":"In a novel combination with another drug","answer_other":"","regimen":12029}],"created":"2020-10-13T22:55:01.536757Z","updated":"2020-10-13T23:01:15.695367Z","dose":"25mg","frequency":"2doses","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6263}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8241,"answer":"Clinical assessment","answer_other":"","report":6263}],"how_diagnosis":[{"id":14018,"answer":"Clinical assessment","answer_other":"","report":6263},{"id":14019,"answer":"Imaging","answer_other":"","report":6263},{"id":14020,"answer":"PCR","answer_other":"","report":6263}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4310,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6263}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-13T22:21:26.005326Z","updated":"2020-10-13T23:01:15.675315Z","title":"Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32267998,"doi":"10.1111/jth.14828","article_url":"https://pubmed.ncbi.nlm.nih.gov/32267998/","pub_year":2020,"published_authors":"Wang J\r\nHajizadeh N\r\nMoore EE\r\nMcIntyre RC\r\nMoore PK\r\nVeress LA\r\nYaffe MB\r\nMoore HB\r\nBarrett CD","article_author_email":"Author email could not be found.","journal":"Journal of thrombosis and haemostasis : JTH","abstract":"A prothrombotic coagulopathy is commonly found in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID-19 respiratory failure is a relatively preserved lung compliance and high Alveolar-arterial oxygen gradient, with pathology reports consistently demonstrating diffuse pulmonary microthrombi on autopsy, all consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of low-compliance in ARDS. The COVID-19 pandemic is overwhelming the world's medical care capacity with unprecedented needs for mechanical ventilators and high rates of mortality once patients progress to needing mechanical ventilation, and in many environments including in parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality and marked improvements in oxygenation. Here we report a series of three patients with severe COVID-19 respiratory failure who were treated with tissue plasminogen activator. All three patients had a temporally related improvement in their respiratory status, with one of them being a durable response.","article_type":"Original","study_type":"Case Series","number_of_patients":3,"article_patient_number":"2","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"51-60 years","sex":"Female","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":true,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5812,6122,8342]},{"id":6264,"regimens":[{"id":12030,"duration":{"id":6028,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":9287,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12030},{"id":9288,"answer":"In a novel combination with another drug","answer_other":"","regimen":12030}],"created":"2020-10-13T23:10:20.861129Z","updated":"2020-10-13T23:15:08.418984Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6264},{"id":12031,"duration":{"id":6029,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":9289,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12031},{"id":9290,"answer":"In a novel combination with another drug","answer_other":"","regimen":12031}],"created":"2020-10-13T23:10:20.868546Z","updated":"2020-10-13T23:15:08.425379Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6264},{"id":12032,"duration":{"id":6030,"approximate_duration":"2hours dose 1/22hours dose 2","dates_unknown":true},"drug":{"id":5812,"name":"Alteplase","url":"cure-api2.ncats.io/v1/drugs/5812","rxNorm_id":null,"notes":null},"use_drug":[{"id":9291,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":12032},{"id":9292,"answer":"In a novel combination with another drug","answer_other":"","regimen":12032}],"created":"2020-10-13T23:10:20.874852Z","updated":"2020-10-13T23:15:08.431335Z","dose":"25mg","frequency":"2doses","route":"IV","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6264}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8242,"answer":"Clinical assessment","answer_other":"","report":6264}],"how_diagnosis":[{"id":14021,"answer":"Clinical assessment","answer_other":"","report":6264},{"id":14022,"answer":"Imaging","answer_other":"","report":6264}],"author_username":"Belinda Nhundu","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4311,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6264}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-10-13T23:01:43.961362Z","updated":"2020-10-13T23:15:08.411331Z","title":"Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32267998,"doi":"10.1111/jth.14828","article_url":"https://pubmed.ncbi.nlm.nih.gov/32267998/","pub_year":2020,"published_authors":"Wang J\r\nHajizadeh N\r\nMoore EE\r\nMcIntyre RC\r\nMoore PK\r\nVeress LA\r\nYaffe MB\r\nMoore HB\r\nBarrett CD","article_author_email":"Author email could not be found.","journal":"Journal of thrombosis and haemostasis : JTH","abstract":"A prothrombotic coagulopathy is commonly found in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID-19 respiratory failure is a relatively preserved lung compliance and high Alveolar-arterial oxygen gradient, with pathology reports consistently demonstrating diffuse pulmonary microthrombi on autopsy, all consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of low-compliance in ARDS. The COVID-19 pandemic is overwhelming the world's medical care capacity with unprecedented needs for mechanical ventilators and high rates of mortality once patients progress to needing mechanical ventilation, and in many environments including in parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality and marked improvements in oxygenation. Here we report a series of three patients with severe COVID-19 respiratory failure who were treated with tissue plasminogen activator. All three patients had a temporally related improvement in their respiratory status, with one of them being a durable response.","article_type":"Original","study_type":"Case Series","number_of_patients":3,"article_patient_number":"3","full_text_available":true,"outcome":"Patient improved","surgery":"No","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[5812,6122,8342]}]